BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rzeniewicz K, Larkin J, Menzies AM, Turajlic S. Immunotherapy use outside clinical trial populations: never say never? Ann Oncol 2021;32:866-80. [PMID: 33771665 DOI: 10.1016/j.annonc.2021.03.199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gu YF, Lin FP, Epstein RJ. How aging of the global population is changing oncology. Ecancermedicalscience 2021;15:ed119. [PMID: 35211208 DOI: 10.3332/ecancer.2021.ed119] [Reference Citation Analysis]
2 Andrikopoulou A, Korakiti AM, Apostolidou K, Dimopoulos MA, Zagouri F. Immune checkpoint inhibitor administration during pregnancy: a case series. ESMO Open 2021;6:100262. [PMID: 34487972 DOI: 10.1016/j.esmoop.2021.100262] [Reference Citation Analysis]
3 Bossi P, Lorini L. Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations. Dermatol Pract Concept 2021;11:e2021170S. [PMID: 34877078 DOI: 10.5826/dpc.11S2a170S] [Reference Citation Analysis]
4 Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
5 Switzer B, Haanen J, Lorigan PC, Puzanov I, Turajlic S. Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002835. [PMID: 34272309 DOI: 10.1136/jitc-2021-002835] [Reference Citation Analysis]